trac and power3 genes knock-out allogeneic cd19-targeting car-t cell
Trade name: Athena Car-T
Cell therapyexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 6, 2023 (NCT06014073)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06373991 | Phase 1 | Jul 24, 2024 | Changping Laboratory, EdiGene (GuangZhou) Inc., Henan Medical University |
| NCT06014073 | Phase 1/Phase 2 (Phase 2) | Sep 6, 2023 | EdiGene (GuangZhou) Inc., Peking University, People's Liberation Army of China |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EdiGene (GuangZhou) Inc. | For profit | 2 | 1 | 2 | 2023 |
| Changping Laboratory | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Henan Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2023 |
5 organizations
Page 1 / 1